Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (311) Ceftin (cefuroxime axetil), GlaxoSmithKline,
...Newly Approved Drug Therapies (311) Ceftin (cefuroxime axetil), GlaxoSmithKline, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Ceftin (cefuroxime axetil) Company: GlaxoSmithKline Approval Status: Approved September 1997 Treatment Area: acute bronchitis General Information Ceftin ...
View Page

2.  CenterWatch: New Medical Therapies in Disease Category (558), Chronic Bronchitis
...from their phase III ABS program indicated that Factive was significantly superiority to approved therapies (cefuroxime and trovafloxacin) in both clinical success at end of therapy (89.3% vs. 77%; p ...
...response compared to a number of approved therapies (including clarithromycin, levofloxacin, trovafloxacin, amoxicillin-clavulanate, ceftriaxone/cefuroxime and ofloxacin). Factive is currently approved to treat AECB and community-acquired pneumonia; in is ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (184), Sinus Infections
...from their phase III ABS program indicated that Factive was significantly superiority to approved therapies (cefuroxime and trovafloxacin) in both clinical success at end of therapy (89.3% vs. 77%; p ...
...response compared to a number of approved therapies (including clarithromycin, levofloxacin, trovafloxacin, amoxicillin-clavulanate, ceftriaxone/cefuroxime and ofloxacin). Factive is currently approved to treat AECB and community-acquired pneumonia; in is ...
View Page

4.  Newly Approved Drug Therapies (853) Ketek (telithromycin), Sanofi-aventis,
...up of 85.2% compared with 82.0% for subjects who received the comparator drug (cefuroxime axetil). A third study compared 5 days with 10 days of KETEK for the treatment ...
...up of 86.4% compared with 83.1% for subjects who received the comparator drug (cefuroxime axetil). Data showed that subjects who received Ketek showed a clinical cure rate at post ...
View Page

5.  CenterWatch Clinical Industry Provider Profile(4601), SNBL Clinical Pharmacology Center, Inc., Baltimore, MD
...Medical Corps, USAR Major Research Interests: • Adult Vaccine Development (Pneumococcal, Influenza, Pertussis) • Antibiotic Development Trials (Cefuroxime, Sparfloxacin, Levofloxacin, Clinafloxacin) Stephan A. Bart, M.D., CPI - Chief Medical Officer Board Certification: • American ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (465), Bacterial Infections
...from their phase III ABS program indicated that Factive was significantly superiority to approved therapies (cefuroxime and trovafloxacin) in both clinical success at end of therapy (89.3% vs. 77%; p ...
...response compared to a number of approved therapies (including clarithromycin, levofloxacin, trovafloxacin, amoxicillin-clavulanate, ceftriaxone/cefuroxime and ofloxacin). Factive is currently approved to treat AECB and community-acquired pneumonia; in is ...
View Page

7.  CenterWatch: Pulmonary/Respiratory Diseases Approved Drug Therapies
...serious lower respiratory tract disease in infants, Approved June 1998 Drugs Approved in 1997 Ceftin (cefuroxime axetil) ; GlaxoSmithKline; Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997 Cipro (ciprofloxacin ...
View Page

8. Clinical Trial Results by Drug Names
...10 15             Cetamine 2 TDS 10 13 21599/4622 Bronchitis NOS 4 -1 -7 8 Cefuroxime 500 mg 4 8 21599/4623 Bronchitis NOS 3 -2 -8 11 Clarithromycin 500 mg ...
View Page

9.  CenterWatch: List of Newly Approved Drug Thearapies
...Sustained-Release Tablets ; GlaxoSmithKline; Treatment for smoking cessation, Approved May 1997 Pulmonary/Respiratory Diseases Ceftin (cefuroxime axetil) ; GlaxoSmithKline; Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997 Cipro (ciprofloxacin ...
View Page